HOME > OUR WORLD > ABOUT US > CORPORATE OVERVIEW

CORPORATE OVERVIEW

AN INNOVATION LED TRANSNATIONAL PHARMACEUTICAL COMPANY

HEADQUARTERED IN MUMBAI, INDIA, LUPIN LIMITED TODAY IS AN INNOVATION LED TRANSNATIONAL PHARMACEUTICAL COMPANY PRODUCING A WIDE RANGE OF QUALITY, AFFORDABLE GENERIC AND BRANDED FORMULATIONS AND APIs FOR THE DEVELOPED AND DEVELOPING MARKETS OF THE WORLD.

Dr. Desh Bandhu Gupta's vision and dream to fight life threatening infectious diseases and to manufacture drugs of the highest social priority led to the formation of Lupin in the year 1968. His vision, his inimitable commitment and verve have steered Lupin to achieving the distinction of becoming one of the fastest growing generic pharmaceutical companies globally. Lupin first gained recognition when it became one of the world's largest manufacturers of Tuberculosis drugs. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.

The Company's R&D endeavors have resulted in significant progress in its NCE program. The Company's foray into Advanced Drug Delivery Systems has resulted in the development of platform technologies that are being used to develop value-added generic pharmaceuticals. Lupin's world class manufacturing facilities, spread across India and Japan, have played a critical role in enabling the Company to realize its global aspirations. Benchmarked to international standards, these facilities are approved by international regulatory agencies like US FDA, UK MHRA, Japan's MHLW, TGA Australia, WHO, and the MCC South Africa. Our Drugs and products reach over 100 countries in the world.

Lupin is the 12th and 8th largest generics pharmaceutical company by market capitalization (March 31st, 2018, Bloomberg) and revenues (December 30th 2017, Bloomberg LTM) respectively. The Company is the 4th largest pharmaceutical player in the US by prescriptions (IQVIA MAT March 2018); 3rd largest Indian pharmaceutical company by global revenues (December 30th 2017, Bloomberg LTM); 6th largest generic pharmaceutical player in Japan and 5th largest company in the Indian Pharmaceutical Market (IQVIA MAT March 2018). For the financial year ended 31st March, 2018, Lupin’s Consolidated sales and Net profits were at Rs. 155,598 million (USD 2.41 billion) and Rs. 2,513 million (USD 39 million) respectively.

"Embedded in Lupin is a formula for growth which fuels creativity, performance and innovation"

Dr. Desh Bandhu Gupta

Founder and Chairman
download financial highlights